비교리스트

 카트 문의
시장보고서
상품코드
1443368

콜레스테롤 저하제 시장 : 약물 유형별, 질환 유형별, 유통 채널별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율 및 예측(2024-2032년)

Cholesterol-lowering Drug Market, By Drug class, By Disease type, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 288 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

세계 콜레스테롤 저하제 시장 규모는 2023년 184억 87만 달러에 달했고, 2024-2032년 연평균 3.4% 성장할 것으로 예상됩니다.

콜레스테롤 강하제 시장 - 시장 역학

고콜레스테롤의 악영향에 대한 인식이 높아지면서 시장 수요가 증가

고콜레스테롤의 부작용에 대한 인식이 높아짐에 따라 콜레스테롤 저하제 세계 시장이 크게 성장하고 있습니다. 이러한 성장으로 인해 각 제약사들은 환자의 예후를 개선할 수 있는 내약성이 우수한 약물을 찾기 위해 대규모 임상시험을 진행하게 되었습니다. 또한, 신약 개발을 위한 벰페도산의 도입과 함께 이 분야의 활발한 R&D 활동이 시장 성장에 기여하고 있습니다. 비스타틴 사용자들을 위한 새로운 약물 계열의 출현이 시장 성장을 견인하고 있습니다. 그러나 스타틴 사용자 증가와 다양한 가이드라인에서 고지혈증 치료제 사용을 권장하고 있어 시장 확대를 더욱 촉진하고 있습니다. 콜레스테롤 수치가 높아지면 뇌졸중과 심근경색 위험이 증가하며, 고콜레스테롤혈증은 심혈관 질환(CVD), 만성 신장 질환, 2형 당뇨병과 같은 동반 질환에 대한 취약성이 증가합니다. 이러한 요인들이 시장 성장을 더욱 촉진하는 요인으로 작용하고 있습니다. 벰페도산, PCSK9 억제제와 같은 치료제의 도입은 시장의 지속적인 확대에 기여할 것으로 예상됩니다.

콜레스테롤 강하제 시장 - 주요 인사이트

당사의 리서치 애널리스트의 분석에 따르면, 세계 시장은 예측 기간(2024-2032년) 동안 연평균 약 3.4%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

약물 유형별로는 스타틴이 2023년 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.

질병 유형별로는 2023년 고콜레스테롤혈증이 주요 유형으로 나타났습니다.

지역별로는 북미가 2023년에 가장 큰 수익을 창출할 주요 시장입니다.

콜레스테롤 강하제 시장 - 세분화 분석 :

콜레스테롤 강하제 세계 시장은 약제 유형별, 질환 유형별, 유통 채널별, 지역별 등으로 구분됩니다.

약물 유형별로는 복합제, PCSK9 억제제, 콜레스테롤 흡수 억제제, 담즙산 분비 억제제, 스타틴계 약물 등 5가지로 분류됩니다. 스타틴 계열의 약물이 세계 콜레스테롤 저하제 시장에서 가장 큰 비중을 차지하고 있는데, 이는 주로 벰페도산, PCSK9 억제제 등 효과적인 치료제의 도입으로 인한 것입니다.

고콜레스테롤혈증, 심혈관질환, 고지혈증, 기타 등 4가지 질병 유형으로 분류됩니다. 콜레스테롤 저하제 시장의 질병 유형 중 고콜레스테롤혈증은 압도적으로 높은 비중을 차지하고 있습니다. 고콜레스테롤혈증은 혈중 콜레스테롤 수치 상승을 특징으로 하며, 심혈관 질환과 밀접한 관련이 있어 콜레스테롤 저하제의 주요 타겟이 되고 있습니다. 죽상동맥경화증의 주요 원인인 고콜레스테롤혈증은 심장 관련 질환의 심각한 위험 요인입니다. 이에 따라 제약사들은 스타틴, PCSK9 억제제 등 고콜레스테롤혈증에 대응하고 심혈관계 질환의 위험을 줄이기 위해 고콜레스테롤혈증에 특화된 약물의 개발 및 판매에 많은 투자를 하고 있습니다. 전 세계적인 고콜레스테롤혈증 유행은 콜레스테롤 저하제 개발 및 시장 트렌드를 형성하는 데 있어 그 우위를 강조하고 있습니다.

콜레스테롤 강하제 시장 - 지리적 통찰력

지리적으로 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카에 분포되어 있습니다. 이 지역은 비즈니스를 가져 오는 국가에 따라 더 세분화됩니다.

콜레스테롤 강하제 시장 - 경쟁 구도 :

콜레스테롤 강하제 시장의 기업들은 진화하는 순환기 건강 및 개인 맞춤형 의료의 전망을 전략적으로 탐색하고 있습니다. 현재 진행 중인 연구 개발은 새로운 치료 타겟을 발굴하고, 효능이 뛰어나고 부작용이 적은 차세대 콜레스테롤 저하제를 개발하는 데 초점을 맞추었습니다. 의료 서비스 제공업체, 연구기관, 규제기관과의 전략적 협력 관계는 임상시험을 수행하고 새로운 약물 제제 시장 승인을 획득하는 데 도움이 되고 있습니다. 또한, 콜레스테롤 관리의 중요성과 심혈관 질환 예방에 있어 이러한 약물의 역할을 강조하기 위해 교육 이니셔티브와 인식 개선 캠페인을 진행하고 있습니다. 시장이 개인화된 치료 접근법으로 전환함에 따라 기업들은 정밀의료 전략에 투자하고, 유전적 요인을 탐구하고, 혁신적인 기술을 활용하여 환자 개개인의 필요에 따라 콜레스테롤 저하 요법을 맞춤화하기 위해 노력하고 있습니다. 콜레스테롤 저하제 시장은 심혈관 질환을 퇴치하고 전반적인 심장 건강을 개선하기 위한 전 세계 노력에 필수적인 역할을 하고 있습니다.

목차

제1장 콜레스테롤 저하제 시장 개요

  • 조사 범위
  • 시장 추정 연도

제2장 주요 요약

  • 시장 내역
  • 경쟁 인사이트

제3장 콜레스테롤 저하제 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 향후 시장 동향

제4장 콜레스테롤 저하제산업 조사

  • PEST 분석
  • Porter의 Five Forces 분석
  • 성장 전망 매핑
  • 규제 구조 분석

제5장 콜레스테롤 저하제 시장 : COVID-19의 영향 분석

  • COVID-19 이전의 영향 분석
  • COVID-19 이후의 영향 분석

제6장 콜레스테롤 저하제 시장 구도

  • 콜레스테롤 저하제 시장 점유율 분석, 2023년
  • 주요 제조업체별 분석 데이터
    • 기존 기업 분석
    • 신규 기업 분석

제7장 콜레스테롤 저하제 시장 : 약제 클래스별

  • 개요
    • 부문 점유율 분석 : 약제 클래스별
    • 배합제
    • Pcsk9 억제제
    • 콜레스테롤 흡수 억제제
    • 담즙산 분비 억제제
    • 스타틴

제8장 콜레스테롤 저하제 시장 : 질환 유형별

  • 개요
    • 부문 점유율 분석 : 질환 유형별
    • 고콜레스테롤혈증
    • 심혈관질환
    • 고지혈증
    • 기타

제9장 콜레스테롤 저하제 시장 : 유통 채널별

  • 개요
    • 부문 점유율 분석 : 유통 채널별
    • 병원 약국
    • 온라인 약국
    • 소매 약국
    • 기타

제10장 콜레스테롤 저하제 시장 : 지역별

  • 서론
  • 북미
    • 개요
    • 북미 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽 주요 제조업체
    • 독일
    • 이탈리아
    • 영국
    • 프랑스
    • 러시아
    • 네덜란드
    • 스웨덴
    • 폴란드
    • 기타
  • 아시아태평양
    • 개요
    • 아시아태평양 주요 제조업체
    • 인도
    • 중국
    • 일본
    • 한국
    • 호주
    • 태국
    • 인도네시아
    • 필리핀
    • 기타
  • 라틴아메리카
    • 개요
    • 라틴아메리카 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제11장 주요 벤더 분석 : 콜레스테롤 저하제산업

  • 경쟁 대시보드
  • 기업 개요
    • Daiichi Sankyo
    • Merck &Co., Inc.
    • AstraZeneca
    • Esperion Therapeutics and CJ Healthcare
    • Sanofi
    • Amgen, Inc.
    • Pfizer, Inc,
    • Merck &Co., Inc.
    • AbbVie, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Novartis AG
    • GlaxoSmithKline plc.
    • 기타

제12장 애널리스트의 전방위 전망

LSH 24.03.15

REPORT HIGHLIGHT

Cholesterol-lowering Drug Market size was valued at USD 18,400.87 Million in 2023, expanding at a CAGR of 3.4% from 2024 to 2032.

Cholesterol is categorized within the class of steroids, which are organic molecules and a type of lipids. It serves as a crucial structural component in the membranes of animal cells and is biosynthesized by all animal cells. The significance of cholesterol lies in its role in the biological synthesis of steroid hormones such as testosterone and estrogen, vitamin D, and bile acids. The primary sources of cholesterol production include poultry, meat, eggs, and dairy products. Elevated cholesterol levels can result from genetic diseases, obesity, an unhealthy diet, and various other medical conditions. The market for cholesterol-lowering drugs encompasses pharmaceuticals designed to decrease elevated cholesterol levels in the bloodstream, with a primary focus on reducing low-density lipoprotein (LDL) cholesterol. These drugs play a pivotal role in managing cardiovascular health by lowering the risk of atherosclerosis and related complications. As conditions like hypercholesterolemia and cardiovascular diseases become more prevalent globally, cholesterol-lowering drugs, such as statins, PCSK9 inhibitors, and bile acid sequestrants, are commonly prescribed to regulate cholesterol levels and mitigate the risk of heart-related conditions.

Cholesterol-lowering Drug Market- Market Dynamics

Increasing awareness of high cholesterol's adverse effects to propel market demand

The global Cholesterol-lowering Drug market is experiencing significant growth, driven by increasing awareness of high cholesterol's adverse effects. This growth has prompted manufacturers to conduct extensive investigational studies to identify well-tolerated drugs for improved patient outcomes. Furthermore, robust research and development activities in the sector, along with the incorporation of bempedoic acid for developing new drugs, contribute to the market's growth. The emergence of new drug classes catering to non-statin users is boosting market growth. However, the rising number of statin users and the endorsement of antihyperlipidemic adoption by various guidelines further propel market expansion. Elevated cholesterol levels increase the risks of stroke and myocardial infarction, while hypercholesterolemia is linked to increased vulnerability to cardiovascular diseases (CVD) and comorbidities like chronic kidney disease and type 2 diabetes. These factors act as additional drivers for market growth. The introduction of therapies such as bempedoic acid, PCSK9 inhibitors, and other drugs is expected to contribute to the market's continued expansion.

Cholesterol-lowering Drug Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.4% over the forecast period (2024-2032)

Based on drug class segmentation, statins was predicted to show maximum market share in the year 2023

Based on disease type segmentation, hypercholesterolemia was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Cholesterol-lowering Drug Market- Segmentation Analysis:

The Global Cholesterol-lowering Drug Market is segmented on the basis of Drug class, Disease type, Distribution Channel, and Region.

The market is divided into five categories based on drug class: combination drugs, PCSK9 inhibitors, cholesterol absorption inhibitors, bile acid sequestrants, and statins. The statins segment commands the largest portion of the global cholesterol-lowering drug market, primarily due to the introduction of effective therapies such as bempedoic acid and PCSK9 inhibitors.

The market is divided into four categories based on disease type: Hypercholesterolemia, Cardiovascular Diseases, Hyperlipidaemia, Others. Among the disease types in the cholesterol-lowering drug market, hypercholesterolemia stands out as a dominant focus. Hypercholesterolemia, characterized by elevated levels of cholesterol in the blood, is a primary target for cholesterol-lowering drugs due to its strong association with cardiovascular diseases. As a key contributor to atherosclerosis, hypercholesterolemia is a significant risk factor for heart-related conditions. Consequently, pharmaceutical companies are heavily invested in developing and marketing drugs, such as statins and PCSK9 inhibitors, specifically tailored to address hypercholesterolemia and mitigate the risk of cardiovascular events. The prevalence of hypercholesterolemia worldwide underscores its dominance in shaping the landscape of cholesterol-lowering drug development and market trends.

Cholesterol-lowering Drug Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Cholesterol-lowering Drug Market- Competitive Landscape:

Companies in the cholesterol-lowering drug market are strategically navigating the evolving landscape of cardiovascular health and personalized medicine. Ongoing research and development efforts focus on the discovery of novel therapeutic targets and the development of next-generation cholesterol-lowering drugs with improved efficacy and fewer side effects. Strategic collaborations with healthcare providers, research institutions, and regulatory bodies aid in conducting clinical trials and gaining market approvals for new drug formulations. Additionally, educational initiatives and awareness campaigns are undertaken to highlight the importance of cholesterol management and the role of these drugs in preventing cardiovascular events. As the market shifts towards personalized treatment approaches, companies are investing in precision medicine strategies, exploring genetic factors, and leveraging innovative technologies to tailor cholesterol-lowering therapies for individual patient needs. The cholesterol-lowering drug market remains integral to global efforts in combating cardiovascular diseases and improving overall heart health.

Recent Developments:

In 2021, Inclisiran received approval for NHS use following clinical trials that demonstrated its ability to reduce LDL cholesterol levels by approximately 50%. According to NHS England, Inclisiran, marketed under the brand name Leqvio, has the potential to avert 55,000 heart attacks and strokes, leading to an estimated 30,000 lives saved by the year 2031.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Daiichi Sankyo

Merck & Co., Inc.

AstraZeneca

Esperion Therapeutics and CJ Healthcare

Sanofi

Amgen, Inc.

Pfizer, Inc,

Merck & Co., Inc.

AbbVie, Inc.

Sun Pharmaceutical Industries Ltd.

Takeda Pharmaceutical Company Limited

Novartis AG

GlaxoSmithKline plc.

Others

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Combination drugs
  • Pcsk9 inhibitors
  • Cholesterol absorption inhibitors
  • Bile acid sequestrants
  • Statins

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Hypercholesterolemia
  • Cardiovascular Diseases
  • Hyperlipidaemia
  • Others

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Others

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Cholesterol-lowering Drug Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Cholesterol-lowering Drug Market Snippet by Drug class
    • 2.1.2. Cholesterol-lowering Drug Market Snippet by Disease type
    • 2.1.3. Cholesterol-lowering Drug Market Snippet by Distribution channel
    • 2.1.4. Cholesterol-lowering Drug Market Snippet by Country
    • 2.1.5. Cholesterol-lowering Drug Market Snippet by Region
  • 2.2. Competitive Insights

3. Cholesterol-lowering Drug Key Market Trends

  • 3.1. Cholesterol-lowering Drug Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Cholesterol-lowering Drug Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Cholesterol-lowering Drug Market Opportunities
  • 3.4. Cholesterol-lowering Drug Market Future Trends

4. Cholesterol-lowering Drug Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Cholesterol-lowering Drug Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Cholesterol-lowering Drug Market Landscape

  • 6.1. Cholesterol-lowering Drug Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Cholesterol-lowering Drug Market - By Drug class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug class, 2023 & 2032 (%)
    • 7.1.2. Combination drugs
    • 7.1.3. Pcsk9 inhibitors
    • 7.1.4. Cholesterol absorption inhibitors
    • 7.1.5. Bile acid sequestrants
    • 7.1.6. Statins

8. Cholesterol-lowering Drug Market - By Disease type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Disease type, 2023 & 2032 (%)
    • 8.1.2. Hypercholesterolemia
    • 8.1.3. Cardiovascular Diseases
    • 8.1.4. Hyperlipidaemia
    • 8.1.5. Others

9. Cholesterol-lowering Drug Market - By Distribution channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution channel, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Online Pharmacies
    • 9.1.4. Retail Pharmacies
    • 9.1.5. Others

10. Cholesterol-lowering Drug Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Cholesterol-lowering Drug Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Cholesterol-lowering Drug Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Cholesterol-lowering Drug Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Cholesterol-lowering Drug Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Cholesterol-lowering Drug Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Cholesterol-lowering Drug Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Daiichi Sankyo
    • 11.2.2. Merck & Co., Inc.
    • 11.2.3. AstraZeneca
    • 11.2.4. Esperion Therapeutics and CJ Healthcare
    • 11.2.5. Sanofi
    • 11.2.6. Amgen, Inc.
    • 11.2.7. Pfizer, Inc,
    • 11.2.8. Merck & Co., Inc.
    • 11.2.9. AbbVie, Inc.
    • 11.2.10. Sun Pharmaceutical Industries Ltd.
    • 11.2.11. Takeda Pharmaceutical Company Limited
    • 11.2.12. Novartis AG
    • 11.2.13. GlaxoSmithKline plc.
    • 11.2.14. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제